JP2009503072A5 - - Google Patents

Download PDF

Info

Publication number
JP2009503072A5
JP2009503072A5 JP2008525035A JP2008525035A JP2009503072A5 JP 2009503072 A5 JP2009503072 A5 JP 2009503072A5 JP 2008525035 A JP2008525035 A JP 2008525035A JP 2008525035 A JP2008525035 A JP 2008525035A JP 2009503072 A5 JP2009503072 A5 JP 2009503072A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glioma
tert
butylnitrone
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008525035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009503072A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/029152 external-priority patent/WO2007019065A2/en
Publication of JP2009503072A publication Critical patent/JP2009503072A/ja
Publication of JP2009503072A5 publication Critical patent/JP2009503072A5/ja
Withdrawn legal-status Critical Current

Links

JP2008525035A 2005-08-04 2006-07-28 退形成性神経膠腫に対する補助的化学療法 Withdrawn JP2009503072A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70572105P 2005-08-04 2005-08-04
PCT/US2006/029152 WO2007019065A2 (en) 2005-08-04 2006-07-28 Adjuvant chemotherapy for anaplastic gliomas

Publications (2)

Publication Number Publication Date
JP2009503072A JP2009503072A (ja) 2009-01-29
JP2009503072A5 true JP2009503072A5 (enExample) 2009-09-10

Family

ID=37727837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008525035A Withdrawn JP2009503072A (ja) 2005-08-04 2006-07-28 退形成性神経膠腫に対する補助的化学療法

Country Status (6)

Country Link
US (1) US20070032453A1 (enExample)
EP (1) EP1922075A4 (enExample)
JP (1) JP2009503072A (enExample)
AU (1) AU2006278741A1 (enExample)
CA (1) CA2617492A1 (enExample)
WO (1) WO2007019065A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005106871A (ru) 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
US7723301B2 (en) * 2007-08-29 2010-05-25 The Board Of Trustees Of The University Of Arkansas Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US8633249B2 (en) 2008-09-02 2014-01-21 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
JP5242651B2 (ja) * 2010-09-24 2013-07-24 株式会社東芝 レポーター遺伝子構築物、アッセイキットおよび検出方法
CA3074102A1 (en) 2017-09-20 2019-03-28 Oklahoma Medical Research Foundation Treatment of drug resistant gliomas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4928835A (en) * 1989-01-31 1990-05-29 Continental Pet Technologies, Inc. Injection molded preform, method of treating same and container formed therefrom
US5766909A (en) * 1992-02-04 1998-06-16 Merck & Co., Inc. DNA encoding inducible nitric oxide synthase
US5569902A (en) * 1995-01-17 1996-10-29 Welch Allyn, Inc. Contact two-dimensional bar code reader having pressure actuated switch
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
EP1267860A1 (en) * 2000-03-30 2003-01-02 Oklahoma Medical Research Foundation Butylnitrone containing compositions for inhibition of cancer development
EP1525003A1 (en) * 2002-06-28 2005-04-27 Pharmacia Corporation Methods and contrast agents useful in quantifying nitric oxide

Similar Documents

Publication Publication Date Title
KR102283895B1 (ko) 제약 조합물
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2013501731A5 (enExample)
JP2015187125A5 (enExample)
ZA200309905B (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia.
Holzbeierlein Managing complications of androgen deprivation therapy for prostate cancer
WO2015120289A1 (en) Methods and compositions for treating abnormal cell growth
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
RU2020107732A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
JP2020500864A5 (enExample)
Jeong et al. Coniferyl aldehyde attenuates radiation enteropathy by inhibiting cell death and promoting endothelial cell function
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
WO2009071095A2 (en) Prevention of hyperthermia subsequent to hypothermia treatment of ischemia
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2009503072A5 (enExample)
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
AU2017247008A1 (en) Isoflavonoid composition with improved pharmacokinetics
McQueen et al. Adjuvant ketamine analgesia for the management of cancer pain
JP2020519576A5 (enExample)
Arakawa et al. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma
JP2005513167A5 (enExample)
Hah et al. Dietary alpha lipoic acid supplementation prevents synovial inflammation and bone destruction in collagen-induced arthritic mice
Borgo et al. Effect of tamoxifen on the coronary vascular reactivity of spontaneously hypertensive female rats
JP2004500411A5 (enExample)